Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Evotec SE

Start price
Target price
Perf. (%)
€13.99
23.02.24
€15.00
23.02.25
4.93%
29.03.24

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Well known brand
Fibrogen Inc.

Start price
Target price
Perf. (%)
€1.80
23.02.24
€0.000
23.02.25
-41.03%
12.05.24

Fibrogen Inc.

Start price
Target price
Perf. (%)
€1.80
23.02.24
€0.000
23.02.25
-41.03%
12.05.24

buy
Fibrogen Inc.

Start price
Target price
Perf. (%)
€1.89
23.02.24
-
23.02.25
-14.29%
04.03.24

Iovance Biotherapeutics Inc.

Start price
Target price
Perf. (%)
€14.71
23.02.24
-
23.02.25
6.05%
02.03.24

Fibrogen Inc.

Start price
Target price
Perf. (%)
€1.55
22.02.24
-
22.02.25
4.52%
02.03.24

Very low/no dividend yield expected
Risky Investment
EBIT decline/stagnation expected
High valuation
Emergent Biosolutions Inc.

Start price
Target price
Perf. (%)
€2.38
21.02.24
-
21.02.25
30.70%
01.03.24

Emergent Biosolutions Inc.

Start price
Target price
Perf. (%)
€2.86
21.02.24
-
21.02.25
8.94%
02.03.24

Good culture
Probably not worthwhile Investment
No uniques
Emergent Biosolutions Inc.

Start price
Target price
Perf. (%)
€2.86
21.02.24
-
21.02.25
9.43%
01.03.24

Ryman Healthcare Group Ltd.

Start price
Target price
Perf. (%)
€2.60
21.02.24
-
21.03.24
-3.04%
02.03.24

buy
Elekta Ab B

Start price
Target price
Perf. (%)
€6.92
19.02.24
-
19.03.24
-1.70%
20.03.24

Fibrogen Inc.

Start price
Target price
Perf. (%)
€2.14
19.02.24
-
19.02.25
-24.30%
02.03.24

buy
Fibrogen Inc.

Start price
Target price
Perf. (%)
€2.14
19.02.24
-
19.02.25
-24.30%
03.03.24

Probably not worthwhile Investment
buy
Evotec SE

Start price
Target price
Perf. (%)
€13.70
17.02.24
€14.00
17.02.25
2.15%
23.02.24

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Well known brand
Fibrogen Inc.

Start price
Target price
Perf. (%)
€2.02
13.02.24
-
13.02.25
5.94%
17.02.24

Probably not worthwhile Investment
Fibrogen Inc.

Start price
Target price
Perf. (%)
€2.36
13.02.24
-
13.02.25
-9.32%
17.02.24

buy
Fibrogen Inc.

Start price
Target price
Perf. (%)
€2.36
13.02.24
-
13.02.25
-9.32%
18.02.24

Probably not worthwhile Investment
Fibrogen Inc.

Start price
Target price
Perf. (%)
€2.54
12.02.24
-
12.02.25
-15.75%
18.02.24

Fibrogen Inc.

Start price
Target price
Perf. (%)
€1.72
05.02.24
-
05.02.25
24.42%
17.02.24

Very low/no dividend yield expected
Risky Investment
EBIT decline/stagnation expected
High valuation
buy
Uniqure B.V.

Start price
Target price
Perf. (%)
€4.92
04.02.24
-
04.02.25
11.79%
17.02.24

buy
Viatris Inc.

Start price
Target price
Perf. (%)
€10.90
03.02.24
-
03.02.25
4.61%
02.03.24

Fibrogen Inc.

Start price
Target price
Perf. (%)
€1.81
03.02.24
€1.00
03.02.25
18.23%
17.02.24

Fibrogen Inc.

Start price
Target price
Perf. (%)
€1.98
01.02.24
-
01.02.25
-8.59%
03.02.24

Fibrogen Inc.

Start price
Target price
Perf. (%)
€1.64
29.01.24
-
29.01.25
10.37%
02.02.24

buy
Fibrogen Inc.

Start price
Target price
Perf. (%)
€1.54
29.01.24
-
29.01.25
17.53%
03.02.24